

## Lipids

# Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review

Alexander Vonbank<sup>1,2,3†</sup>, Heinz Drexel<sup>2,3,4,5\*†</sup>, Stefan Agewall<sup>6,7</sup>, Basil S. Lewis<sup>8,9</sup>, Joern F. Dopheide<sup>5</sup>, Keld Kjeldsen<sup>10,11</sup>, Claudio Ceconi<sup>12</sup>, Gianluigi Savarese<sup>13</sup>, Giuseppe Rosano<sup>14</sup>, Sven Wassmann<sup>15</sup>, Alexander Niessner<sup>16</sup>, Thomas Andersen Schmidt<sup>17,18</sup>, Christoph H. Saely<sup>1,2,3,5</sup>, Iris Baumgartner<sup>5</sup>, and Juan Tamargo<sup>19</sup>

<sup>1</sup>Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; <sup>2</sup>Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; <sup>3</sup>Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; <sup>4</sup>Drexel University College of Medicine, Philadelphia, PA, USA; <sup>5</sup>Division of Angiology, Swiss Cardiovascular Center, University Hospital Bern, Switzerland; <sup>6</sup>Department of Cardiology, Ullevål, Oslo University Hospital, Oslo, Norway; <sup>7</sup>Institute of Clinical Sciences, Sørstjerhjemmet, University of Oslo, Oslo, Norway; <sup>8</sup>Lady Davis Carmel Medical Center, Haifa, Israel; <sup>9</sup>Technion-Israel Institute of Technology, Ruth and Bruce Rappaport School of Medicine, Haifa, Israel; <sup>10</sup>Division of Cardiology, Department of Medicine, Copenhagen University Hospital, Copenhagen, Denmark; <sup>11</sup>Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark; <sup>12</sup>Department of Medical Science, University of Ferrara, Ferrara, Italy; <sup>13</sup>Department of Medicine, Cardiology Division, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden; <sup>14</sup>Department of Medical Sciences, Irccs San Raffaele Hospital, Rome, Italy; <sup>15</sup>Cardiology Pasing, Munich, Germany and University of the Saarland, Homburg, Saar, Germany; <sup>16</sup>Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; <sup>17</sup>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; <sup>18</sup>Department of Emergency Medicine, Holbaek Hospital, University of Copenhagen, Denmark; and <sup>19</sup>Department of Pharmacology, School of Medicine, Universidad Complutense, Ciudad Universitaria, Madrid, Spain

Received 14 June 2018; revised 22 July 2018; editorial decision 23 July 2018; accepted 6 August 2018; online publish-ahead-of-print 7 August 2018

With statins, the reported rate of adverse events differs widely between randomized clinical trials (RCTs) and observations in clinical practice, the rates being 1–2% in RCTs vs. 10–20% in the so-called real world. One possible explanation is the claim that RCTs mostly use a run-in period with a statin. This would exclude intolerant patients from remaining in the trial and therefore favour a bias towards lower rates of intolerance. We here review data from RCTs with more than 1000 participants with and without a run-in period, which were included in the Cholesterol Treatment Trialists Collaboration. Two major conclusions arise: (i) the majority of RCTs did not have a test dose of a statin in the run-in phase. (ii) A test dose in the run-in phase was not associated with a significantly improved adherence rate within that trial when compared to trials without a test dose. Taken together, the RCTs of statins reviewed here do not suggest a bias towards an artificially higher adherence rate because of a run-in period with a test dose of the statin. Other possible explanations for the apparent disparity between RCTs and real-world observations are also included in this review albeit mostly not supported by scientific data.

## Keywords

Statin therapy • Adherence • Run in phase • Intolerance

## Introduction

Randomized controlled trials (RCTs), especially when large, double-blind, and placebo-controlled, are the best method for evaluating the efficacy, safety, and tolerability of statin treatment.<sup>1,2</sup> A further advantage is that both, known and—more

importantly—unknown confounders are equally distributed between the treatment arms.

There is overwhelming evidence from numerous RCTs that inhibitors of HMG-CoA reductase (statins) substantially reduce the risk of myocardial infarction, stroke, and other manifestations of atherosclerotic cardiovascular disease. Furthermore, analysis of the Cholesterol

\* Corresponding author. Tel: +43 5522 303 2670, Fax: +43 5522 303 7533, Email: [vivit@lkh.at](mailto:vivit@lkh.at); [heinz@lkh.at](mailto:heinz@lkh.at)

† The first two authors contributed equally to the study.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

Treatment Trialists' Collaboration (CTTC) showed that statin therapy substantially reduces the risk of vascular mortality by about one-fifth per each mmol/L reduction in LDL cholesterol (Table 1).<sup>3</sup>

In addition to results from RCTs, during the approximately 4 decades since their introduction, statins have been demonstrated to be safe and well tolerated.<sup>4,5</sup> Adverse effects of statin in RCTs, as recently reviewed<sup>6</sup> are mainly myopathy with reportedly 1–2% under statin, with similar incidence in placebo arms.<sup>3</sup> Sometimes, however, their perceived tolerability has declined. Some investigators nowadays suggest that 10–20% of patients are unable to tolerate statins, either completely or at a higher dose. Consequently, poor adherence in the real-world setting has become an important problem.<sup>7,8</sup>

Specifically, for the case of statin trials, there is an often raised claim that RCTs excluded patients with statin intolerance in the pre-randomization or run-in periods in order to minimize losses from follow-up, a fact that could explain why randomized trials had lower rates of side effects in the active treatment phase than will be observed in the real world.<sup>9</sup>

The Physicians' Health Study exemplifies the use of a pre-randomization run-in period to exclude subjects who are more likely to become non-adherent. The underlying rationale was that run-in periods can dilute or enhance the clinical applicability of the results of a clinical trial, depending on the patient group who will receive the therapy.<sup>10</sup> Thus, adherence data from clinical trials using run-in periods should clarify how this aspect of their design affects the applicability of the results to clinical practice.

The hypothesis of the present investigation was that there are more side effects and non-adherence in trials without a run-in period. We analysed the data from RCTs selected by the CTTC involving 175 000 participants.<sup>3</sup>

## Selection of sources

We aimed to include all eligible statin trials from the CTTC protocols. The CTTC protocol was first established in 1994 to reliably assess

mortality outcome in particular types of patients. Randomized trials were eligible for inclusion if the main effect of at least one of the trial interventions was to modify lipid levels, the trial was un-confounded with respect to the intervention and the trial aimed to recruit at least 1000 participants with treatment duration of at least 2 years.<sup>11</sup> The main outcome measure in these trials were major vascular events.

From the 27 trials included in CTTC and the Heart Protection Study (HPS)-2 trial, 15 trials had a run-in period (Figure 1). Among the 15 trials with a run-in period, 12 trials used no statin in the run-in period and 3 trials used a statin therapy in the run-in phase. We here evaluate the adherence rates in these trials, both for statins and for placebo.

Next, we tested whether the use of statins in the run-in phase affected the rate of non-compliance during the trial both in patients receiving statins and those receiving placebo.

## Medication in run-in phase

### Adherence rate in Cholesterol Treatment Trialists Collaboration trials without a run-in period

From the 27 CTTC trials, 13 trials had no run-in period.


In the MEGA trial 8214 men and postmenopausal women aged 40–70 years were included and randomized to diet or diet plus pravastatin (10–20 mg daily). The mean follow-up was about 5.3 years. The adherence rate was 65.6% in the diet and 65.8% in the diet plus pravastatin group over 5-year follow-up.<sup>12</sup>

In the ALERT trial 2102 renal transplant recipients, men and women aged 30–75 years, were included and randomized to fluvastatin XL (80 mg/day) or placebo. Patients with a pre-existing statin therapy were excluded. The mean follow-up was about 5.1 years. The adherence rate was 74.9% in the fluvastatin group and 71.5% in the placebo group.<sup>13</sup>

The CARDS trial with 2838 men and women with type 2 diabetes aged 40–75 years in 132 UK and Ireland centres to placebo or

**Table 1** Studies with a run-in phase

Study with run-in period	Number of patients	Placebo/comparator	Study drug	Duration
SSSS	4444	Placebo	Simvastatin 20 mg	5.4 years
ASCOT	10 305	Placebo	Atorvastatin 0 mg	5 years
ASPEN	2901	Placebo	Atorvastatin 10 mg	4 years
AFCAPS/TextCAPS	6695	Placebo	Lovastatin 20 mg (40 mg)	5.2 years
GISSI	4271	Placebo	Pravastatin 20 mg	23 months
HPS	20 536	Placebo	Simvastatin 20 mg	5 years
HPS 2	36 059	Placebo	ERN/LRPT	3.6 years
CORONA	5459	Placebo	Rosuvastatin 10 mg	32.8 months
TNT	10 003	Atorvastatin 10 mg	Atorvastatin 80 mg	5.5 years
Lipid Study Group	9014	Placebo	Pravastatin	6.1 years
PROSPER	5804	Placebo	Pravastatin 40 mg	3.2 years
JUPITER	17 802	Placebo	Rosuvastatin 20 mg	1.9 years
SEARCH	12 064	Simvastatin 20 mg	Simvastatin 80 mg	84 months
WOSCOPS	6596	Placebo	Pravastatin 40 mg	4.9 years
German Diabetes and Dialysis Study	1255	Placebo	Atorvastatin 20 mg	4 years



atorvastatin. The mean duration of follow-up was 3.9 years. The trial was terminated earlier because of the pre-specified rule for efficacy. The adherence rate was >99% in both groups.<sup>14</sup>

In the ALLHAT-LLT trial, a subset of 10 355 patients were randomized to a lipid-lowering component with pravastatin 40 mg/day or usual care. The follow-up was 4.9 years. There is no concrete information on adherence in the lipid subgroup.<sup>15</sup>

In the post-coronary artery bypass graft (CABG) trial 1351 men and women, aged 21 to 74 years, who had undergone a coronary bypass surgery 1–11 years before baseline. Patients were randomized to aggressive vs. moderate lipid-lowering therapy with lovastatin (mean 76 mg daily) and cholestyramine (8 g per day) if necessary. An angiography was repeated after an average of 4.2 years. The adherence in both statin groups was 85 to 90%. The cholestyramine adherence was lower (65%).<sup>16</sup>

The CARE trial included 4159 patients, men and postmenopausal women aged 21–74 years with myocardial infarction who were randomized to pravastatin (40 mg/day) or placebo. In the last year of follow-up, 86% of the placebo group and 94% of the treatment group were taking their study medication. The median duration of follow-up was 5.0 years.<sup>17</sup>

In the ALLIANCE trial 2442 patients, men and women >18 years, with coronary heart disease were randomized to an aggressive treatment arm using atorvastatin (80 mg/day) or usual care followed over 51.5 months. The adherence was 78.7% in the aggressive treatment arm and 76.8% in the usual care arm.<sup>18</sup>

In the LIPS trial 1677 patients, men and women aged 18–80 years with stable or unstable angina, were randomly assigned to treatment with fluvastatin or placebo. The median follow-up was 3.9 years. The adherence was 93.1% in the fluvastatin group and 92.1% in the placebo group.<sup>19</sup>

The AURORA trial included 2776 men and women aged 50–80 years who were undergoing maintenance dialysis. They were randomized to rosuvastatin 10 mg daily or placebo. The median follow-up period was 3.8 years. According to tablet counts, 91.7% of rosuvastatin and 89.5% of placebo tablets were taken as prescribed.<sup>20</sup>

The 4D trial included 1255 subjects, men and women 18–80 years, with type 2 diabetes receiving maintenance haemodialysis. They were

randomly assigned to atorvastatin 20 mg per day or placebo. The median follow-up time was about 4 years. In the placebo group, 82% of patients took the study medication without interruption and in the atorvastatin group 80% of patients did so.<sup>21</sup>

The A-Z trial compared in phase Z in 4497 patients with acute coronary syndrome aged 21–80 years with a less aggressive treatment strategy with placebo (for 30 days) then simvastatin 20 mg or more aggressive with simvastatin 40 mg (for 30 days) and then 80 mg. The adherence rate was about 68% in the low aggressive group and about 66% in the more aggressive group. They were randomized to either an early intensive treatment strategy (40 mg/day of simvastatin for 30 days and then 80 mg/day of simvastatin thereafter) or a less aggressive strategy (placebo for 4 months and then 20 mg/day of simvastatin thereafter).<sup>22</sup>

The PROVE-IT trial randomized 4162 patients, men and women at least 18 years old, who were hospitalized for an acute coronary syndrome to a treatment group with pravastatin 40 mg or a group with atorvastatin 80 mg. The follow-up was up to 36 months. The adherence rate has not been reported in detail from this trial.<sup>23</sup>

The IDEAL trial enrolled 8888 patients, men and women, aged <80 years with a history of acute myocardial infarction. They compared usual dose simvastatin (20 mg/day) or high dose of atorvastatin (80 mg/day). The follow-up was about 4.8 years. The adherence was 95% in both groups.<sup>24</sup>

In synopsis, thus, in those trials that had no run-in phase, the adherence rate was very similar in patients receiving statins and in those receiving placebo.

## Adherence rate in Cholesterol Treatment Trialists Collaboration trials with a run-in period

From the 27 CTTC trials plus HPS-2, 15 trials had a run-in period (Figure 1).

The 4S trial randomized 4444 men and women aged 35–70 with a history of angina pectoris or myocardial infarction from 94 Scandinavian centres. The protocol included a 2-week placebo run-in phase. There was no significant difference in discontinuation [288 (13%) patients in placebo group vs. 231 (10%) in the statin group].<sup>25</sup>

A similar report exists from the ASCOT-LLA trial with 10 305 hypertensive patients aged 40–79 and a total cholesterol of 6.5 mmol/L or less. There was a 4-week run-in period. In the atorvastatin group (10 mg/day), 240 patients (2.3%) discontinued atorvastatin vs. 276 (2.6%) in the placebo group.<sup>26</sup>

In the ASPEN trial, 3598 men and women with type 2 diabetes aged 40–75 years had a 6-week run-in phase, 67.5% in the Atorvastatin group (10 mg/day) and 57.6% in placebo group were taking study medication at study completion.<sup>27</sup>

The AFCAPS/TexCAPS included 6605 men and women aged 45–73 years. There was a 2-week placebo run-in phase, 969 patients (14.6%) withdrew in the Lovastatin group vs. 1220 (18.4%) in the placebo group.<sup>28</sup>

The HPS study with 20 536 participants (men and women) with coronary disease or other occlusive arterial disease aged 40–80 years had a 4-week placebo run-in phase and showed an adherence rate of 99.6% in the simvastatin (20 mg/day) intervention group vs. 99.7% in the placebo group.<sup>29</sup>

The CORONA trial included 5459 participants of at least 60 years of age. Eligible patients were treated with single blind placebo for 2–4 weeks before randomization to demonstrate compliance. After 33 months of follow-up, median rosuvastatin (10 mg/day) was discontinued in 546 patients in the rosuvastatin group (10%) vs. 490 in the placebo group (8.9%), the difference was not statistically significant.<sup>30</sup>

A similar result was shown in the PROSPER trial with 5804 men and women aged 70–82 years, with a history or risk for vascular disease. The eligible patients entered a 4-week single blind placebo lead-in period. Participants who used less than 75% or more than 120% of the placebo medication were excluded: 725 (12.5%) patients discontinued in the placebo group vs. 724 (12.5%) in the pravastatin group (40 mg/day) during a follow-up of 3.2 years.<sup>31</sup>

In the JUPITER trial, 17 802 healthy men 50 years and women 60 years or older were included. They had no history of coronary artery disease (CAD) or lipid-lowering medication. All eligible subjects underwent a 4-week run-in phase during which they received placebo. The adherence rate was about 75% at the time the study was terminated. There are no data on the comparison of placebo and verum. We should mention that the patients received rosuvastatin 20 mg daily. The trial was stopped after a median follow-up of 1.9 years.<sup>32</sup>

The SEARCH study with 12 064 patients aged between 18 and 80 years with a history of myocardial infarction had a run-in phase with simvastatin 20 mg. In the active phase of the trial, the patients were then randomized to 80 mg simvastatin or 20 mg simvastatin. The adherence after 84 months was 77% in the simvastatin 80 mg group vs. 69% in the simvastatin 20 mg group.<sup>33</sup>


The WOSCOPS trial compared pravastatin 40 mg with placebo in 6596 patients in a 4.9 year follow-up. The patients got a lipid-lowering advice after 1 week and a control diet for 4 weeks before randomization. The adherence rate was 69.2% in the placebo group and 71.4% in the pravastatin group, respectively.<sup>34</sup>

The GDDS trial included 1255 patients with type 2 diabetes at the age of 18–80 years with haemodialysis for less than 2 years. The patients were randomized to atorvastatin 20 mg or placebo, after a 4-week run-in phase with placebo. After a 4 year follow-up, the adherence rate was 80% in the treatment group and 82% in the placebo group.<sup>35</sup>

The HPS 2 trial included 25 673 patients with occlusive arterial disease. There was a 4-week run-in phase with simvastatin 40 mg. If the participants did not reach the treatment goal they received ezetimibe on top. The proportion of participants taking at least 80% of their study medication was 92, 89, and 85% after 1, 2, and 3 years follow-up, respectively.<sup>29</sup>

The GISSI-P trial included 4271 patients with acute myocardial infarction. The population on which the cholesterol-lowering treatment was tested (pravastatin 20 mg daily) was derived from a broader cohort randomized to supplements of n-3 polyunsaturated fatty acids, vitamin E, or standard treatment over 6 months. The median follow-up was about 23 months.<sup>36</sup>

In synopsis thus, there is no indication that—in studies using a run-in phase—a difference existed in adherence between participants allocated to placebo or to statins. Moreover, and most importantly, there is no significant difference in adherence rates between trials using or not using statins in the run-in phase (Figure 2). A run-in phase statin use cannot be a cause for the low rate of statin non-adherence in RCTs.



**Figure 2** Adherence rates in relation to run-in phase. Mean  $\pm$  SD adherence rates in statin trials with vs. without statin therapy in run-in period.

The general value of run-in phases in RCTs has recently been challenged in investigations on DPP4 inhibitors and statins.<sup>37,38</sup> The authors had focused on efficacy and safety, but not on adherence rates. Taken together with our results, statins in the run-in phase are time-consuming and appear not essential for the conduct of RCTs.

## Other causes for non-adherence in the real world vs. RCT's

In general, non-adherence in real-world settings can exceed 50% in some populations, and this situation also pertains to non-medication treatment recommendations such as monitoring blood glucose or exercising regularly.<sup>39,40</sup> Multiple factors contribute to real-world non-adherence, including high medication costs, complexity and duration of the medication regimen, disruption of lifestyle, younger age, asymptomatic chronic disease, the patient's opinion of benefits and risks, and poor communication between doctor and patient.<sup>41,42</sup> Treatment factors, particularly side effects such as weight gain or sexual dysfunction, patient factors, such as the desire to be independent and eschew the healthcare system, and illness factors (including psychosis, depression, or cognitive impairment) are also important contributors to non-adherence.<sup>43</sup>

Importantly, non-adherence during the conduct of a clinical trial will include most types of non-adherence encountered in real world plus several behaviours unique to clinical trials that are termed, according to Shiovitz *et al.* as 'artificial' non-adherence.<sup>44</sup> When adherence is not monitored, there is a general assumption that adherence is almost ideal in clinical trial settings.<sup>45</sup> However, there is extensive evidence to the contrary: both real world and the unique forms of non-adherence abound in clinical trials.<sup>46</sup> Artificial non-adherence is completely different from real-world non-adherence; it is also contrary to both the clinical trial protocol and the agreements in the informed consent process. Examples of these specific and intentional behaviours include denying previous or ongoing study participation while enrolling in multiple studies with an intention to collect stipends, but pretending to have the medical interest.<sup>44</sup>

Although real-world studies have been extremely valuable for identifying associations of risk factors with disease (e.g. blood pressure, blood sugar, and cholesterol with cardiovascular disease), their



value for the assessment of treatment effects is more limited. Real-world studies also have the potential to detect large adverse event rates on health outcomes that would not normally be expected to occur. One of the best examples certainly is myopathy with statin therapy.<sup>47</sup> The HPS study exemplifies very well that patients asked about muscle complaints frequently agree to have muscle pain; however this statement was at the same frequency found in placebo patients.

Because of the potential biases inherent in observational studies, they cannot be relied on for demonstrating the causal nature of treatment-related associations when the relative risks are moderate or relate to health outcomes that are common in the types of patients studied.<sup>48–53</sup> Thus, when large-scale evidence from randomized controlled trials does exist, the additional value of information from non-randomized observational studies about treatment effects is very limited because no causal proof exists.<sup>47</sup>

Contrary to a common belief, adequate data about the use of a treatment in healthcare databases might not involve a duration of exposure that is longer than in the randomized trials.<sup>54–56</sup> Another important fact is that potential biases in observational studies of treatment are often underestimated in the interpretation of associations that are found with health outcomes. Compared with the situation in randomized controlled trials with masked treatment, patients are treated in daily practice knowing that they are taking a particular drug.<sup>48–50,53,57</sup> Confounding by indication, or contraindication, occurs when the treatment being considered tends to be provided more, or less, often to individuals with medical conditions or other characteristics that are associated with increased, or decreased, risks of various health outcomes (which is, of course, what would be expected to occur in clinical practice).<sup>58</sup> Hence, confounders for side effects occur in the real world that are controlled for by randomization in RCTs.

Moreover, there is a high probability of a placebo effect. Typically, in a pre-medication discussion, physicians tell patients that the treatment could have potential side effects. This effect is so-called the placebo effect which refers by definition to the induction or the worsening of symptoms induced by sham or active therapies. Examples are numerous and concern both clinical trials and daily practice. The underlying mechanisms are, on one hand, psychological (conditioning and negative expectations) and, on the other hand, neurobiological (role of cholecystokinin, endogenous opioids, and dopamine). Placebo effects can modulate the outcome of a given therapy in a negative way, as do placebo effects in a positive way.<sup>59</sup> Importantly, in RCTs placebo effects will be distributed evenly between active drug and placebo if the expected side effect is explained equally. As indicated above, myopathy rates in the HPS trial (high but equal with placebo and active drug) are a good example.

A recent review of the evidence from randomized trials and observational studies suggested that symptomatic adverse events may be misattributed to statins,<sup>50</sup> and there is further evidence from trials of statins of this misattribution.<sup>60</sup> Uncertainty about the association between muscle symptoms and statins persists due to limitations of observational studies and trials. For example, a major limitation of observational studies is a lack of blinding, patients taking a medication expect to experience adverse effects,<sup>61</sup> and therefore reporting of symptoms in statin users may be higher than in a comparable population not on statins. Furthermore, many patients start with exercise after a cardiovascular event at the same time as statin therapy is initiated, so the causal muscle pain is pushed to statin therapy.

Often forgotten is that tolerability is a patient-defined entity and not an objectively defined one but a feeling of treated subjects. In addition to all above-mentioned reasons, there is place for irrationality.

Data on adherence and persistence should ideally be derived from real-life studies. Several patient-related, physician-related, and health system-related factors influence adherence behaviour.<sup>62</sup> Non-adherence may arise from low social status, suboptimal health literacy, lack of involvement in treatment decision-making, comorbidity and subsequent polypharmacy, communication barriers, uncertainty about the drug effectiveness, serious adverse events occurring during therapy, limited access to care, and lack of health information technology and high copayments.<sup>62,63</sup>

## Conclusion

### If RCT's have no confounder, real-world data must have

In clinical practice, management of patients with statin intolerance or those with statin associated muscle symptoms is often difficult.<sup>64</sup> Strategies for keeping patients on statin therapy and improving the adherence have been proposed most recently by two position papers of the ESC working group of cardiovascular pharmacotherapy<sup>7</sup> and another group.<sup>65</sup>

In most patients, statin associated muscle symptoms are not of pharmacological origin, but rather a consequence of the high prevalence of any other background muscle symptoms coupled with patient expectations that muscle pain or damage may occur. This problem is aggravated by lay press misinformation. In observational studies of patients prescribed statins in clinical practice, adverse event rates, especially muscle symptoms, obtained per questionnaire are substantial, but muscle symptoms are also very common in patients allocated to placebo. Association is not causation and an adverse event is not necessarily an adverse effect. In RCT's, in which treatment is blinded and the placebo effect applies equally to the statin and placebo groups, there is little difference between statin and placebo in the rates of withdrawal due to adverse events of any kind, showing that statins can be tolerated by nearly all patients, including those with advanced disease and complex medical history.

### Ways to solution

There appear three levels for a possible progress in statin adherence rate. First, physicians should explain causality of benefit and lack of causation of side effects with statins. Second, patients must be educated on the long-term value to reduce hard endpoints. Third, the public high-quality media must be informed and convinced of the benefit/risk ratio of statins.

**Conflict of interest:** none declared.

## References

- Maningat P, Breslow JL. Needed, pragmatic clinical trials for statin-intolerant patients. *N Engl J Med* 2011;**365**:2250–2251.
- Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. *J Clin Lipidol* 2014;**8**:554–561.

3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;**380**:581–590.
4. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhalra N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;**7**:e29849.
5. Karlsson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. *Eur Heart J Cardiovasc Pharmacother* 2016;**2**:212–217.
6. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoğlu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy, Perception vs. the evidence—focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J* 2018;**39**:2526–2539.
7. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saelly CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J* 2017;**38**:2473–2479.
8. Deshpande S, Quek RGW, Forbes CA, de Kock S, Kleijnen J, Gandra SR, Simpson RJ. A systematic review to assess adherence and persistence with statins. *Curr Med Res Opin* 2017;**33**:769–778.
9. Tobert JA, Newman CB. Statin tolerability: in defence of placebo-controlled trials. *Eur J Prev Cardiol* 2016;**23**:891–896.
10. Vera MA, D, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. *Br J Clin Pharmacol* 2014;**78**:684–698.
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**:1267–1278.
12. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 2006;**368**:1155–1163.
13. Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer H-H, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. *Kidney Int* 2004;**66**:1549–1555.
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004;**364**:685–696.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002;**288**:2998–3007.
16. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med* 1997;**336**:153–162.
17. Sacks FM, Pfeffer MA, Moyer LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;**335**:1001–1009.
18. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. *J Am Coll Cardiol* 2004;**44**:1772–1779.
19. Serruys PW, de Feyter P, Macaya C, Kokkott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;**287**:3215–3222.
20. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae D-W, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving H-H, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med* 2009;**360**:1395–1407.
21. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;**353**:238–248.
22. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004;**292**:1307–1316.
23. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;**350**:1495–1504.
24. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 2005;**294**:2437–2445.
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;**344**:1383–1389.
26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;**361**:1149–1158.
27. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 2006;**29**:1478–1485.
28. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Krueyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;**279**:1615–1622.
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;**360**:7–22.
30. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaefelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;**357**:2248–2261.
31. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;**360**:1623–1630.
32. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;**359**:2195–2207.
33. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010;**376**:1658–1669.
34. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. *N Engl J Med* 2007;**357**:1477–1486.
35. Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Schmagl H, Winkler K, Holme I, Holdaas H, Wanner C. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. *Clin J Am Soc Nephrol* 2011;**6**:1316–1325.
36. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet* 1999;**354**:447–455.
37. Fralick M, Avorn J, Franklin JM, Bartsch E, Abdurrobb A, Kesselheim AS. Application and impact of run-in studies for the evaluation of statin efficacy and safety. *J Gen Intern Med* 2018;**33**:792–794.
38. Fralick M, Avorn J, Franklin JM, Abdurrobb A, Kesselheim AS. Application and impact of run-in studies. *J Gen Intern Med* 2018;**33**:759–763.

39. Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. *Am J Med Sci* 2007;**334**:248–254.
40. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;**353**:487–497.
41. Shiovitz TM, Wilcox CS, Gevorgyan L, Shawkat A. CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry. *Innov Clin Neurosci* 2013;**10**:17–21.
42. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. NICE clinical guideline 76. [www.nice.org.uk/guidance/cg76](http://www.nice.org.uk/guidance/cg76) (April 2018).
43. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. *Adv Psychiatr Treat* 2007;**13**:336–346.
44. Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, Burch D. Mitigating the effects of nonadherence in clinical trials. *J Clin Pharmacol* 2016;**56**:1151–1164.
45. Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. *Clin Pharmacol Ther* 2014;**95**:617–626.
46. Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance, compliance, and compliance. *Mol Interv* 2011;**11**:107–110.
47. Armitage J, Baigent C, Collins R. Lessons from the controversy over statins—Authors' reply. *Lancet* 2016;**388**:2237–2238.
48. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity. II: Observational studies. *Lancet* 2001;**357**:455–462.
49. Grimes DA, Schulz KF. Bias and causal associations in observational research. *Lancet* 2002;**359**:248–252.
50. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? *N Engl J Med* 2000;**342**:1907–1909.
51. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. *BMJ* 2007;**334**:349–351.
52. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. *JAMA* 1999;**281**:841–844.
53. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. *BMJ* 1998;**316**:140–144.
54. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. *BMJ* 2010;**340**:c2197.
55. García-Rodríguez LA, González-Pérez A, Stang MR, Wallander M-A, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. *Pharmacoevidenciol Drug Saf* 2008;**17**:953–961.
56. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. *JAMA Intern Med* 2013;**173**:1–10.
57. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. *Cochrane Database Syst Rev* 2007;MR000012.
58. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. *BJOG* 2002;**109**:1319–1330.
59. Planès S, Villier C, Mallaret M. The nocebo effect of drugs. *Pharmacol Res Perspect* 2016;**4**:e00208.
60. Pocock SJ. *Clinical Trials*. Chichester: Wiley, 1983.
61. Altman DG, Bland JM. Statistics notes, variables and parameters. *BMJ* 1999;**318**:1667.
62. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? *Curr Atheroscler Rep* 2013;**15**:291.
63. Brown MT, Russell JK. Medication adherence: WHO cares? *Mayo Clin Proc* 2011;**86**:304–314.
64. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, Stroes E, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, Krauss RM, Laufs U, Santos RD, März W, Newman CB, John Chapman M, Ginsberg HN, John Chapman M, Ginsberg HN, de Backer G, Catapano AL, Hegele RA, Kees Hovingh G, Jacobson TA, Leiter L, Mach F, Wiklund O. Statin-associated muscle symptoms, impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015;**36**:1012–1022.
65. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E, Clement-Baudena G, Gropper S, Hamer A, Molemans B, Sourdille T, Tahbaz A, Thorstensen C. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. *Eur Heart J Cardiovasc Pharmacother* 2018;**4**:119–127.